Announcement on Obtaining Drug Registration Certificate
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment
Announcement on Obtaining Drug Registration Certificate
Filed with SSE ·
6ix hasn’t read this filing yet.
Hainan Huluwa Pharmaceutical Group Co. Ltd. on 6ix
Earlier from Hainan Huluwa Pharmaceutical
- Announcement on Wholly-owned Subsidiary Obtaining Drug Registration Certificate for Ambroxol Hydrochloride Oral Drops
- Announcement on Progress in Judicial Auction of Some Shares Held by Controlling Shareholder
- Announcement on Obtaining the Drug Registration Certificate for Ipratropium Bromide Solution for Inhalation
- Announcement on Wholly-Owned Subsidiary Obtaining Drug Registration Certificate for Compound Polyethylene Glycol (3350) Electrolyte Oral Solution
- Announcement on Expected Loss in Performance for 2025
Later from Hainan Huluwa Pharmaceutical
- Announcement on Progress in Implementing Other Risk Warnings for the Company's Stocks
- Announcement on Company Re-certified as High-tech Enterprise
- Announcement on Freezing of Some Shares of Controlling Shareholder
- Announcement on Confirming Remunerations for Directors and Senior Management Members in 2025 and 2026 Remuneration Plan
- Indicative Announcement on the Completion of Judicial Auction and Transfer of Some Shares Held by Controlling Shareholder and Equity Change
Follow Hainan Huluwa Pharmaceutical into a list and get an email when it puts out news.
Follow Hainan Huluwa Pharmaceutical